CRIS

Permanent URI for this communityhttps://cris.ute.edu.ec/handle/123456789/1

Browse

Search Results

Now showing 1 - 10 of 22

Some of the metrics are blocked by your
consent settings
Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis
(Wiley, 2013-02-28)
MARTI CARVAJAL, ARTURO JOSE
;
Luis H Agreda Pérez
;
Ivan Solà
Scopus© Citations 31
Some of the metrics are blocked by your
consent settings
Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases
(Wiley, 2024-09-19)
MARTI CARVAJAL, ARTURO JOSE
;
Mario A Gemmato-Valecillos
;
Diana Monge Martín
;
Mark Dayer
;
Eduardo Alegría-Barrero
Background: Atherosclerotic cardiovascular disease (ACVD) is worsened by chronic inflammatory diseases. Interleukin receptor antagonists (IL-RAs) and tumour necrosis factor-alpha (TNF) inhibitors have been studied to see if they can prevent cardiovascular events. Objectives: The purpose of this study was to assess the clinical benefits and harms of IL-RAs and TNF inhibitors in the primary and secondary prevention of ACVD. Search methods: The Cochrane Heart Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE (including In-Process & Other Non-Indexed Citations), Ovid Embase, EBSCO CINAHL plus, and clinical trial registries for ongoing and unpublished studies were searched in February 2024. The reference lists of relevant studies, reviews, meta-analyses and health technology reports were searched to identify additional studies. No limitations on language, date of publication or study type were set. Selection criteria: RCTs that recruited people with and without pre-existing ACVD, comparing IL-RAs or TNF inhibitors versus placebo or usual care, were selected. The primary outcomes considered were all-cause mortality, myocardial infarction, unstable angina, and adverse events. Data collection and analysis: Two or more review authors, working independently at each step, selected studies, extracted data, assessed the risk of bias and used GRADE to judge the certainty of evidence. Main results: We included 58 RCTs (22,053 participants; 21,308 analysed), comparing medication efficacy with placebo or usual care. Thirty-four trials focused on primary prevention and 24 on secondary prevention. The interventions included IL-1 RAs (anakinra, canakinumab), IL-6 RA (tocilizumab), TNF-inhibitors (etanercept, infliximab) compared with placebo or usual care. The certainty of evidence was low to very low due to biases and imprecision; all trials had a high risk of bias. Primary prevention: IL-1 RAs  The evidence is very uncertain about the effects of the intervention on all-cause mortality(RR 0.33, 95% CI 0.01 to 7.58, 1 trial), myocardial infarction (RR 0.71, 95% CI 0.04 to 12.48, I² = 39%, 2 trials), unstable angina (RR 0.24, 95% CI 0.03 to 2.11, I² = 0%, 2 trials), stroke (RR 2.42, 95% CI 0.12 to 50.15; 1 trial), adverse events (RR 0.85, 95% CI 0.59 to 1.22, I² = 54%, 3 trials), or infection (rate ratio 0.84, 95% 0.55 to 1.29, I² = 0%, 4 trials). Evidence is very uncertain about whether anakinra and cankinumab may reduce heart failure (RR 0.21, 95% CI 0.05 to 0.94, I² = 0%, 3 trials). Peripheral vascular disease (PVD) was not reported as an outcome. IL-6 RAs The evidence is very uncertain about the effects of the intervention on all-cause mortality (RR 0.68, 95% CI 0.12 to 3.74, I² = 30%, 3 trials), myocardial infarction (RR 0.27, 95% CI 0.04 to1.68, I² = 0%, 3 trials), heart failure (RR 1.02, 95% CI 0.11 to 9.63, I² = 0%, 2 trials), PVD (RR 2.94, 95% CI 0.12 to 71.47, 1 trial), stroke (RR 0.34, 95% CI 0.01 to 8.14, 1 trial), or any infection (rate ratio 1.10, 95% CI: 0.88 to 1.37, I2 = 18%, 5 trials). Adverse events may increase (RR 1.13, 95% CI 1.04 to 1.23, I² = 33%, 5 trials). No trial assessed unstable angina. TNF inhibitors The evidence is very uncertain about the effects of the intervention on all-cause mortality (RR 1.78, 95% CI 0.63 to 4.99, I² = 10%, 3 trials), myocardial infarction (RR 2.61, 95% CI 0.11 to 62.26, 1 trial), stroke (RR 0.46, 95% CI 0.08 to 2.80, I² = 0%; 3 trials), heart failure (RR 0.85, 95% CI 0.06 to 12.76, 1 trial). Adverse events may increase (RR 1.13, 95% CI 1.01 to 1.25, I² = 51%, 13 trials). No trial assessed unstable angina or PVD. Secondary prevention: IL-1 RAs The evidence is very uncertain about the effects of the intervention on all-cause mortality (RR 0.94, 95% CI 0.84 to 1.06, I² = 0%, 8 trials), unstable angina (RR 0.88, 95% CI 0.65 to 1.19, I² = 0%, 3 trials), PVD (RR 0.85, 95% CI 0.19 to 3.73, I² = 38%, 3 trials), stroke (RR 0.94, 95% CI 0.74 to 1.2, I² = 0%; 7 trials), heart failure (RR 0.91, 95% 0.5 to 1.65, I² = 0%; 7 trials), or adverse events (RR 0.92, 95% CI 0.78 to 1.09, I² = 3%, 4 trials). There may be little to no difference between the groups in myocardial infarction (RR 0.88, 95% CI 0.0.75 to 1.04, I² = 0%, 6 trials). IL6-RAs The evidence is very uncertain about the effects of the intervention on all-cause mortality (RR 1.09, 95% CI 0.61 to 1.96, I² = 0%, 2 trials), myocardial infarction (RR 0.46, 95% CI 0.07 to 3.04, I² = 45%, 3 trials), unstable angina (RR 0.33, 95% CI 0.01 to 8.02, 1 trial), stroke (RR 1.03, 95% CI 0.07 to 16.25, 1 trial), adverse events (RR 0.89, 95% CI 0.76 to 1.05, I² = 0%, 2 trials), or any infection (rate ratio 0.66, 95% CI 0.32 to 1.36, I² = 0%, 4 trials). No trial assessed PVD or heart failure. TNF inhibitors The evidence is very uncertain about the effect of the intervention on all-cause mortality (RR 1.16, 95% CI 0.69 to 1.95, I² = 47%, 5 trials), heart failure (RR 0.92, 95% 0.75 to 1.14, I² = 0%, 4 trials), or adverse events (RR 1.15, 95% CI 0.84 to 1.56, I² = 32%, 2 trials). No trial assessed myocardial infarction, unstable angina, PVD or stroke. Adverse events may be underestimated and benefits inflated due to inadequate reporting. Authors' conclusions: This Cochrane review assessed the benefits and harms of using interleukin-receptor antagonists and tumour necrosis factor inhibitors for primary and secondary prevention of atherosclerotic diseases compared with placebo or usual care. However, the evidence for the predetermined outcomes was deemed low or very low certainty, so there is still a need to determine whether these interventions provide clinical benefits or cause harm from this perspective. In summary, the different biases and imprecision in the included studies limit their external validity and represent a limitation to determining the effectiveness of the intervention for both primary and secondary prevention of ACVD.
Scopus© Citations 4
Some of the metrics are blocked by your
consent settings
Haematological interventions for treating disseminated intravascular coagulation during pregnancy and postpartum
(Wiley, 2011-03-16)
MARTI CARVAJAL, ARTURO JOSE
;
Gabriella Comunián-Carrasco
;
Guiomar E Peña-Martí
Scopus© Citations 16
Some of the metrics are blocked by your
consent settings
Distribution and trends of hematology and oncology research in Latin America: A decade of uncertainty
(Wiley, 2013-12-31)
Andrés M. Acevedo
;
Alexandra Gómez
;
Henry A. Becerra
;
Ana P. Ríos
;
Paula C. Zambrano
<jats:sec><jats:title>BACKGROUND</jats:title><jats:p>Although hematology and oncology research is a highly relevant and evolving field, research contributions by Latin American countries, apart from Brazil, remain unclear.</jats:p></jats:sec><jats:sec><jats:title>METHODS</jats:title><jats:p>The authors performed a bibliometric analysis through a methodical search of the Latin American abstracts presented at 4 main hematology and oncology annual scientific meetings from 2000 to 2010. Latin American regional and national productivity was described through distribution and trend analyses; the subsequent percentage of full‐text publications was also determined.</jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p>In total, 2871 abstracts were identified, of which 1972 abstracts (68.7%) were determined to be original Latin American research and were included in the analysis. Brazil produced by far the most abstracts, with 51.1% of the total, followed by Argentina, Mexico, Peru, Chile, and Uruguay. Together, these 6 countries accounted for 95.2% of the abstracts. Latin America had a positive trend, registering an average increase of 21.5 abstracts per year (<jats:italic>P</jats:italic> < .001). Significant positive growth trends were observed for Brazil, Mexico, Peru, and Uruguay. Argentina and Uruguay were the most productive countries when considering the rate of abstract presentation per population. The full‐text publication rate was 17.9%, and the median time to publication after presentation was 1 year. Brazil prevailed as the leading publishing country (60%), followed by Mexico, Argentina, Peru, Chile, and Cuba, all of which together published 96% of the full‐text articles.</jats:p></jats:sec><jats:sec><jats:title>CONCLUSIONS</jats:title><jats:p>Hematology and oncology research is increasing in Latin America, but this contribution remains limited to a few countries. There is also a low rate of full‐text articles derived from annual scientific meetings. More extensive research is recommended. <jats:bold><jats:italic>Cancer</jats:italic> 2014;120:1237–1245</jats:bold>. © <jats:italic>2013 American Cancer Society</jats:italic>.</jats:p></jats:sec>
Scopus© Citations 19
Some of the metrics are blocked by your
consent settings
Effectiveness of Human Recombinant Activated Protein C for Severe Sepsis and Septic Shock in Adult and Pediatric Patients
(Ovid Technologies (Wolters Kluwer Health), 2013-07)
MARTI CARVAJAL, ARTURO JOSE
;
Christian Gluud
Some of the metrics are blocked by your
consent settings
Identification of biomedical journals in Spain and Latin America
(Wiley, 2015-07-20)
Xavier Bonfill
;
Dimelza Osorio
;
Margarita Posso
;
Ivan Solà
;
Gabriel Rada
<jats:title>Abstract</jats:title><jats:sec><jats:title>Objectives</jats:title><jats:p>Journals in languages other than English that publish original clinical research are often not well covered in the main biomedical databases and therefore often not included in systematic reviews. This study aimed to identify Spanish language biomedical journals from Spain and Latin America and to describe their main features.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Journals were identified in electronic databases, publishers' catalogues and local registries. Eligibility was determined by assessing data from these sources or the journals' websites, when available.</jats:p></jats:sec><jats:sec><jats:title>Findings</jats:title><jats:p>A total of 2457 journals were initially identified; 1498 met inclusion criteria. Spain (27.3%), Mexico (16.0%), Argentina (15.1%) and Chile (11.9%) had the highest number of journals. Most (85.8%) are currently active; 87.8% have an <jats:styled-content style="fixed-case">ISSN</jats:styled-content>. The median and mean length of publication were 22 and 29 years, respectively. A total of 66.0% were indexed in at least one database; 3.0% had an impact factor in 2012. A total of 845 journals had websites (56.4%), of which 700 (82.8%) were searchable and 681 (80.6%) free of charge.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Most of the identified journals have no impact factor or are not indexed in any of the major databases. The list of identified biomedical journals can be a useful resource when conducting hand searching activities and identifying clinical trials that otherwise would not be retrieved.</jats:p></jats:sec>
Scopus© Citations 16
Some of the metrics are blocked by your
consent settings
Prophylactic lidocaine for myocardial infarction
(Wiley, 2015-08-21)
MARTI CARVAJAL, ARTURO JOSE
;
SIMANCAS RACINES, DANIEL ALEJANDRO
;
Vidhu Anand
;
Shrikant I Bangdiwala
Scopus© Citations 49
Some of the metrics are blocked by your
consent settings
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis
(John Wiley & Sons, Ltd, 2013-01-31)
MARTI CARVAJAL, ARTURO JOSE
;
Andrés Felipe Cardona
;
Vidhu Anand
;
Ivan Solà
;
Arturo J Martí-Carvajal
Scopus© Citations 30
Some of the metrics are blocked by your
consent settings
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
(John Wiley & Sons, Ltd, 2013-02-28)
MARTI CARVAJAL, ARTURO JOSE
;
Vidhu Anand
;
Andrés Felipe Cardona
;
Ivan Solà
;
Arturo J Martí-Carvajal
Scopus© Citations 9
Some of the metrics are blocked by your
consent settings
Antibiotics for treating acute chest syndrome in people with sickle cell disease
(John Wiley & Sons, Ltd, 2013-01-31)
MARTI CARVAJAL, ARTURO JOSE
;
Lucieni O Conterno
;
Jennifer M Knight-Madden
;
Arturo J Martí-Carvajal
Scopus© Citations 15

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results